Bupivacaine
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | EXPAREL | — | 2018-04-06 – 2023-11-09 | fda.gov ↗ |
| Approved | EU (EMA) | Zynrelef | — | 2020-09-24 | europa.eu ↗ |
| Approved | US (FDA) | MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE | — | 1972-10-03 | fda.gov ↗ |
Trials 809 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 029 trials · 1 missed | ||||||
| Phase 0 | NCT07643506 | Jun 2026 → Jun 2027 expected | — | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07812259 | May 2026 → Jun 2027 expected | parotid gland neoplasm | Nîmes University Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT07245290 | Nov 2025 → Jun 2026 overdue | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06349772 | Nov 2024 → Nov 2027 expected | — | Texas Tech University Health Sciences Center | Recruiting | No outcome recorded |
| Phase 0 | NCT07826936 | Oct 2024 → Dec 2027 expected | — | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 0 | NCT06462573 | Sep 2024 → Sep 2026 overdue | ureterolithiasis | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05461092 | Jan 2024 → Dec 2026 expected | delirium | University of Iowa | Recruiting | No outcome recorded |
| Phase 0 | NCT05925478 | Nov 2023 → Aug 2024 | acquired aneurysmal subarachnoid hemorrhage | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT05794828 | Sep 2023 → Feb 2025 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT05122351 | Oct 2021 → Dec 2022 | — | Sohag University | Completed | No outcome recorded |
| Phase 0 | NCT05069350 | Sep 2021 → Aug 2022 | — | Research Institute of Ophthalmology, Egypt | Completed | No outcome recorded |
| Phase 0 | NCT05097118 | Sep 2021 → May 2022 | appendicitis | Sohag University | Completed | No outcome recorded |
| Phase 0 | NCT05022160 | Aug → Nov 2021 | prostate neoplasm, urinary bladder neoplasm | Armed Forces Hospital, Pakistan | Unknown | No outcome recorded |
| Phase 0 | NCT04335461 | Aug 2021 → Mar 2023 | — | Montefiore Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT04985500 | Jul 2021 → Dec 2026 expected | — | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04611958 | Jul 2021 | chronic pancreatitis | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 0 | NCT04494880 | Dec 2020 → Dec 2022 | — | State University of New York - Upstate Medical University | Completed | No outcome recorded |
| Phase 0 | NCT04019834 | Jul 2020 → Nov 2021 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 0 | NCT03705637 | Jun 2019 → Mar 2020 | — | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 0 | NCT03867188 | Jan → Jun 2019 | soft tissue sarcoma | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03731221 | Nov 2018 → Sep 2024 | — | The Cleveland Clinic | Completed | Missed primary |
| Phase 0 | NCT03243032 | Oct → Nov 2017 | neuropathy, painful | Satheesh Elangovan | Withdrawn | No outcome recorded |
| Phase 0 | NCT02991404 | Feb → Nov 2017 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 0 | NCT03070054 | Jun 2016 → Mar 2020 | — | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT02740192 | Apr → Dec 2016 | — | Henry Ford Health System | Completed | No outcome recorded |
| Phase 0 | NCT02485145 | Jul → Dec 2015 | osteoarthritis, hand | Transdermal Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 0 | NCT02285491 | Nov 2014 → Nov 2015 | — | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| Phase 0 | NCT00819962 | Sep 2014 → Dec 2015 | — | King Saud University | Unknown | No outcome recorded |
| Phase 0 | NCT00879164 | Apr 2009 → Dec 2010 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 130 trials · 1 met primary | ||||||
| Phase 1 | NCT05575999 | Jan → Oct 2026 expected | — | Kansas City Heart Rhythm Research Foundation | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07429448 | Dec 2025 → Jun 2026 overdue | appendicitis | Sardar Umer Rehman | Recruiting | No outcome recorded |
| Phase 1 | NCT06069791 | Jan 2024 → Dec 2026 expected | — | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT06274008 | Oct 2023 → Oct 2024 | anxiety, opioid abuse | Children's Hospital of Orange County | Unknown | No outcome recorded |
| Phase 1 | NCT04908449 | Jun 2023 → Nov 2024 | coronary artery disorder, respiratory failure | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 1 | NCT05906433 | Jun 2023 → Jun 2025 | osteoarthritis, knee | Foundation for Orthopaedic Research and Education | Completed | No outcome recorded |
| Phase 1 | NCT05664711 | Mar → Dec 2023 | myalgic encephalomeyelitis/chronic fatigue syndrome, post-infectious syndrome, post-viral disorder | Neuroversion, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06620614 | Oct → Dec 2022 | benign prostatic hyperplasia | National Academy of Medical Sciences, Nepal | Completed | No outcome recorded |
| Phase 1 | NCT05517486 | Jul → Aug 2022 | postherpetic neuralgia | Grace Therapeutics Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05588557 | Jul 2022 → Mar 2024 | neuropathy, painful | Nang Kuang Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05062356 | Nov 2021 → Aug 2024 | chronic pain syndrome | St. Mary's Research Center, Canada | Completed | No outcome recorded |
| Phase 1 | NCT05117021 | Nov 2021 → Apr 2022 | — | Sohag University | Unknown | No outcome recorded |
| Phase 1 | NCT04685421 | Jul 2021 → Jun 2023 | heart disorder | Nicklaus Children's Hospital f/k/a Miami Children's Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT04331938 | Nov 2020 → Apr 2024 | acquired aneurysmal subarachnoid hemorrhage, headache disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT03177252 | Oct 2020 → Sep 2021 | brain neoplasm | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT04221568 | Mar 2020 → Mar 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT04189198 | Dec 2019 → Mar 2020 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT04293809 | Dec 2019 → Jan 2020 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04121338 | Dec 2019 → May 2021 | dysautonomia | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT04158102 | Nov → Dec 2019 | — | Nuance Pharma (shanghai) Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04002089 | Jul → Dec 2019 | toe, misshapen | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03729375 | Oct 2018 → Oct 2020 | carpal tunnel syndrome, neuropathy, painful | University of South Florida | Completed | No outcome recorded |
| Phase 1 | NCT03428984 | May → Sep 2018 | — | Pacira Pharmaceuticals, Inc | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03485014 | Apr 2018 → Feb 2019 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03399435 | Jan → Sep 2018 | — | Grünenthal GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT02985762 | Dec 2016 → Sep 2017 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03346993 | Jul 2016 | — | Erzurum Palandöken State Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02681796 | Jun 2016 → Feb 2020 | malignant pancreatic neoplasm | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00485667 | Jun → Aug 2007 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT00119184 | Oct 2002 → Mar 2006 | — | Hadassah Medical Organization | Terminated | Met primary Stop: Enrollment |
| Phase 1/27 trials · 1 missed | ||||||
| Phase 1/2 | NCT07842159 | Sep 2026 → Mar 2028 expected | — | The University of Texas Health Science Center, Houston | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04168710 | May 2025 → May 2027 | — | Yale University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT06809998 | Jan 2025 → Aug 2026 overdue | osteoarthritis, knee | Unity Health Toronto | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03780478 | Jun 2019 → Dec 2021 | — | University of Southern California | Unknown | No outcome recorded |
| Phase 1/2 | NCT03040011 | Jun 2017 → Apr 2019 | pelvic organ prolapse | Lauren Giugale, MD | Completed | Missed primary |
| Phase 1/2 | NCT02214810 | Jan → Sep 2015 | — | Broward Health | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01477190 | Oct 2010 → Oct 2011 | colon carcinoma, diverticulitis, inflammatory bowel disease | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 270 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT07201987 | Jan 2027 → Jan 2028 expected | — | Ganesh M. Shankar | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07796074 | Sep 2026 → Sep 2027 expected | — | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT07366905 | Feb → Mar 2026 | — | Hainan Medical College | Completed | No outcome recorded |
| Phase 2 | NCT06734975 | Jul 2025 → Dec 2026 expected | polyp of vocal cord | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT06635889 | Mar 2025 → Oct 2029 expected | nephrolithiasis | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT06270147 | Nov 2024 → Jan 2025 overdue | substance-related disorder | McMaster University | Recruiting | No outcome recorded |
| Phase 2 | NCT06655454 | Nov 2024 → Jun 2026 overdue | — | New York University | Recruiting | No outcome recorded |
| Phase 2 | NCT04744675 | May → Jul 2024 overdue | complex regional pain syndrome | Ottawa Hospital Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06429501 | Apr 2024 → Feb 2027 expected | — | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06002152 | Nov 2023 → Feb 2026 | — | Yale University | Completed | Missed primary |
| Phase 2 | NCT06411795 | Nov 2023 → Jan 2027 expected | pancreatic neoplasm, tumor of duodenum | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
| Phase 2 | NCT05734625 | Jul 2023 → Feb 2027 expected | migraine disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06766474 | Mar 2023 → Oct 2024 | — | Minia University | Completed | No outcome recorded |
| Phase 2 | NCT05736549 | Feb 2023 → Sep 2027 expected | osteoarthritis, knee | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT04427904 | Jun 2022 → Dec 2024 | thyroid gland disorder | St. Joseph's Healthcare Hamilton | Unknown | No outcome recorded |
| Phase 2 | NCT04911062 | Apr → Jul 2022 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05810012 | Apr → Oct 2022 | — | Pain Medicine Department | Completed | No outcome recorded |
| Phase 2 | NCT04477525 | Jun 2021 → Jun 2022 | neurological pain disorder | Montefiore Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT04717193 | May 2021 → Apr 2023 | appendicitis | University of Alberta | Completed | Mixed |
| Phase 2 | NCT04865211 | Apr 2021 → Feb 2022 | neuropathy, painful | The Cooper Health System | Unknown | No outcome recorded |
| Phase 2 | NCT05044468 | Mar 2021 → May 2028 expected | pleural neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05355597 | Jan 2021 → Mar 2025 | musculoskeletal system disorder, soft tissue neoplasm | Atlantic Health System | Terminated | No outcome recorded |
| Phase 2 | NCT05324995 | Jan 2021 → Feb 2022 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04559347 | Dec 2020 → Jan 2024 | — | Poovendran Saththasivam | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04109885 | Sep 2020 → Jan 2024 | headache disorder | Christian Fromm, MD | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04207411 | Aug 2020 → Oct 2022 | — | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 2 | NCT04189783 | Jun 2020 → Oct 2024 overdue | retroperitoneal sarcoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04244097 | Apr → Jul 2020 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06893601 | Jan → Oct 2020 | — | Aydin Adnan Menderes University | Completed | No outcome recorded |
| Phase 2 | NCT03827213 | Jan 2019 → Jun 2021 | — | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03865147 | Jan → Jul 2019 | — | Medical Ethics UK Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT03958513 | Jan → Jul 2019 | — | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 2 | NCT03695367 | Oct → Nov 2018 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03587636 | Sep 2018 → Mar 2021 | — | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT03545516 | Sep → Nov 2018 | substance-related disorder | Richmond University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03433976 | May 2018 → May 2020 | — | University Hospital, Montpellier | Unknown | Met primary |
| Phase 2 | NCT03393117 | Mar 2018 → Jul 2020 | breast cancer | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03236324 | Sep 2017 → Oct 2022 | — | University of Calgary | Completed | No outcome recorded |
| Phase 2 | NCT03023982 | Feb 2017 → Feb 2019 | — | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03106519 | Jan → Jun 2017 | palmar fibromatosis | Catherine Vandepitte, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT02913573 | Sep 2016 → Sep 2018 | breast neoplasm | Huntington Memorial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02616367 | Dec 2015 → Dec 2016 | osteoarthritis, knee | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT03266081 | Apr 2015 → Aug 2022 | excessive tearing, ptosis | McMaster University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02343263 | Mar 2015 → May 2017 | neuropathy, painful | Indiana University | Terminated | No outcome recorded |
| Phase 2 | NCT02349581 | Nov 2014 → May 2015 | — | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 2 | NCT02188394 | Jul 2014 → Jan 2016 | migraine disorder | César Fernández-de-las-Peñas | Completed | No outcome recorded |
| Phase 2 | NCT02044302 | Apr 2014 → Jan 2016 | — | Yale University | Terminated | No outcome recorded |
| Phase 2 | NCT01969006 | Jan 2014 → Jan 2015 | — | Randers Regional Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01785459 | Oct 2013 → Jul 2016 | — | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01826851 | Mar 2013 → Jun 2017 | coronary artery disorder | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT01878864 | Nov 2012 → Jun 2013 | periodontitis | Ove Andersen | Terminated | No outcome recorded |
| Phase 2 | NCT01667315 | Aug 2012 → Jan 2013 | — | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 2 | NCT02007096 | Aug 2012 → Oct 2014 | abdominal wall malformation | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT01224145 | Mar → Jun 2011 | — | Innocoll | Completed | No outcome recorded |
| Phase 2 | NCT01220024 | Dec 2010 → May 2011 | — | Innocoll | Completed | No outcome recorded |
| Phase 2 | NCT01559740 | Jul → Aug 2010 | — | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT01096966 | Mar 2010 → Feb 2011 | chronic pain syndrome | Durect | Completed | No outcome recorded |
| Phase 2 | NCT01133119 | Feb 2010 → Feb 2013 | — | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 2 | NCT01244932 | Sep 2009 → Jun 2011 | — | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT00993226 | May → Dec 2009 | — | Durect | Completed | Missed primary |
| Phase 2 | NCT01454609 | Jan 2009 → Jul 2010 | — | Jawaharlal Institute of Postgraduate Medical Education & Research | Completed | No outcome recorded |
| Phase 2 | NCT00818363 | Dec 2008 → Oct 2009 | — | Durect | Completed | Missed primary |
| Phase 2 | NCT01701414 | Nov 2008 → Feb 2012 | — | Rhode Island Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00661466 | Jul 2008 → Jan 2009 | — | Innocoll | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01662401 | May 2008 → Jan 2010 | — | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00626886 | Mar 2008 → Jan 2009 | — | Innocoll | Completed | No outcome recorded |
| Phase 2 | NCT00624910 | Dec 2007 → Sep 2008 | — | Innocoll | Completed | No outcome recorded |
| Phase 2 | NCT00974350 | Jan → Oct 2007 | — | Durect | Completed | No outcome recorded |
| Phase 2 | NCT00478179 | Sep 2006 → Dec 2007 | postherpetic neuralgia | Durect | Completed | No outcome recorded |
| Phase 2 | NCT00050362 | Dec 2002 → Oct 2004 | — | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 2/321 trials · 2 met primary | ||||||
| Phase 2/3 | NCT07555821 | Apr → Oct 2026 expected | — | South Egypt Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06456255 | Nov 2024 → May 2025 overdue | hemorrhagic disease, paranasal sinus disorder | Amin Javer | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06621329 | Oct 2024 → Jul 2026 overdue | headache disorder, subarachnoid hemorrhage | University of California, Davis | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05357690 | Apr 2023 → Jun 2026 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT05283980 | Nov 2022 → Mar 2025 overdue | neuropathy, painful, opioid abuse | Beth Israel Deaconess Medical Center | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04655339 | Jan 2020 → Sep 2021 | substance-related disorder | Baylor Research Institute | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05672680 | Dec 2019 → Aug 2023 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2/3 | NCT03739021 | Nov 2019 → Mar 2020 overdue | chronic pain syndrome | University of South Florida | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03408483 | Apr 2018 → May 2019 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2/3 | NCT02495220 | Jul 2015 → Nov 2017 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02393664 | Mar 2015 → Oct 2016 | lung neoplasm | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02374320 | Nov 2014 → Mar 2016 | CREST syndrome, Raynaud disease, diffuse scleroderma | Jose Soberon, MD | Terminated | No outcome recorded |
| Phase 2/3 | NCT03749408 | Dec 2012 → Jun 2014 | pulpitis | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT01683071 | Sep 2012 → Dec 2013 | — | Pacira Pharmaceuticals, Inc | Completed | Met primary |
| Phase 2/3 | NCT01616108 | Apr 2012 → Sep 2019 | Graves disease, esotropia, exotropia, ptosis | Smith-Kettlewell Eye Research Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT02030717 | Feb 2012 → May 2015 | renal cell carcinoma | Umeå University | Completed | No outcome recorded |
| Phase 2/3 | NCT00932542 | Apr 2010 → Feb 2011 | hemorrhoid | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 2/3 | NCT01040273 | Dec 2009 → Dec 2010 | osteoarthritis, hip | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT00298571 | Feb 2006 → Oct 2007 | neuropathy, painful | University of South Florida | Completed | No outcome recorded |
| Phase 2/3 | NCT00472446 | Jan 2006 → Dec 2008 | — | Cantonal Hospital of St. Gallen | Completed | Met primary |
| Phase 2/3 | NCT02847013 | ? → Dec 2019 | — | Milton S. Hershey Medical Center | Withdrawn | No outcome recorded |
| Phase 391 trials · 5 met primary · 5 missed | ||||||
| Phase 3 | NCT07841080 | Oct 2026 → Nov 2029 expected | ventricular fibrillation, ventricular tachycardia | Fondazione IRCCS Policlinico San Matteo di Pavia | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07672236 | Jul → Dec 2026 expected | head and neck cancer, mucositis | OncoZenge AB | Recruiting | No outcome recorded |
| Phase 3 | NCT07212114 | Nov 2025 → Aug 2029 expected | — | Emory University | Recruiting | No outcome recorded |
| Phase 3 | NCT07092566 | Nov 2025 → Oct 2027 expected | renal carcinoma | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT06740214 | Sep 2025 → Jun 2027 expected | — | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 3 | NCT07257874 | Jul → Dec 2025 | — | Islamabad Medical and Dental College | Completed | No outcome recorded |
| Phase 3 | NCT06937385 | May 2025 → May 2026 overdue | cranial neuralgia, migraine disorder | HCA Florida North Florida Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06989866 | Dec 2024 → Aug 2026 overdue | — | United States Naval Medical Center, Portsmouth | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06665438 | Dec 2024 → Apr 2025 overdue | — | Al-Azhar University | Recruiting | No outcome recorded |
| Phase 3 | NCT06695858 | Nov 2024 → Oct 2025 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT06405724 | May 2024 → Dec 2025 | — | Feng Gao | Unknown | No outcome recorded |
| Phase 3 | NCT06349668 | Apr 2024 → Oct 2027 expected | congenital anomaly of kidney and urinary tract, kidney benign neoplasm, kidney cancer, ureter benign neoplasm +3 | Hans Bahlmann | Recruiting | No outcome recorded |
| Phase 3 | NCT05427500 | Mar 2024 → Jan 2026 overdue | post-traumatic stress disorder | The Royal's Institute of Mental Health Research | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06313632 | Mar 2024 → Mar 2025 | pleural disorder | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 3 | NCT06301503 | Mar → May 2024 | — | Udayana University | Completed | No outcome recorded |
| Phase 3 | NCT06430112 | Nov 2023 → May 2024 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT06088082 | Oct 2023 → Apr 2024 | — | King Saud Medical City | Unknown | No outcome recorded |
| Phase 3 | NCT05751421 | Feb 2023 → Feb 2024 | neuropathy, painful | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT05702827 | Jan 2023 → Mar 2024 | female stress incontinence, vulvar disease | TriHealth Inc. | Completed | No outcome recorded |
| Phase 3 | NCT07469826 | Oct 2022 → Apr 2023 | — | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| Phase 3 | NCT03883763 | Apr 2022 → Apr 2023 | — | Cristália Produtos Químicos Farmacêuticos Ltda. | Unknown | No outcome recorded |
| Phase 3 | NCT05264805 | Mar → Sep 2022 | neuropathy, painful | Hamdard University | Unknown | No outcome recorded |
| Phase 3 | NCT05300685 | Feb 2022 → May 2026 | urethral stricture | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT05191745 | Jan 2022 → Apr 2023 | — | Jewish General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05133687 | Nov 2021 → May 2022 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05171179 | Oct 2021 → May 2025 | — | Northwestern University | Completed | No outcome recorded |
| Phase 3 | NCT04826484 | Oct 2021 → Apr 2023 | cryptorchidism, hydrocele, hypospadias, urinary system disorder | Johns Hopkins University | Terminated | Missed primary |
| Phase 3 | NCT05285800 | Sep 2021 → Mar 2022 | — | Hamdard University | Completed | No outcome recorded |
| Phase 3 | NCT04974385 | Aug 2021 → Apr 2022 | — | University of Virginia | Completed | No outcome recorded |
| Phase 3 | NCT04928352 | Jun 2021 → Nov 2026 expected | cleft palate | Assiut University | Recruiting | No outcome recorded |
| Phase 3 | NCT04785625 | Apr → Oct 2021 | abdominal wall malformation, neuropathy, painful | Innocoll | Completed | Met primary |
| Phase 3 | NCT04117074 | Apr 2021 → Mar 2025 | — | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 3 | NCT04785638 | Apr 2021 → Jan 2023 | — | Innocoll | Completed | No outcome recorded |
| Phase 3 | NCT04764916 | Feb 2021 → Feb 2022 | — | Carilion Clinic | Unknown | No outcome recorded |
| Phase 3 | NCT04504812 | Feb 2021 → Apr 2025 | osteoarthritis, knee | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT04468542 | Jan 2021 → Dec 2022 | — | University of South Florida | Unknown | No outcome recorded |
| Phase 3 | NCT04173312 | Jan 2021 → Jan 2023 | — | Ascension Health | Unknown | No outcome recorded |
| Phase 3 | NCT04518462 | Oct 2020 → Apr 2021 | tarsal coalition, toe, misshapen | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT05084573 | Aug 2020 → Jul 2022 | — | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT04910165 | Jun 2020 → Sep 2021 | arthropathy, substance-related disorder | St. Luke's Hospital, Pennsylvania | Completed | No outcome recorded |
| Phase 3 | NCT04426500 | Nov 2019 → Feb 2021 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 3 | NCT03974932 | Jun 2019 → Dec 2020 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT04461028 | Feb 2019 → Jun 2022 | rotator cuff syndrome | University of Pennsylvania | Withdrawn | No outcome recorded |
| Phase 3 | NCT03762343 | Jan 2019 → Dec 2020 | infratentorial neoplasm | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03639389 | Jan 2019 → Mar 2022 | — | Karolinska Institutet | Completed | No outcome recorded |
| Phase 3 | NCT03508830 | Dec 2018 → Jan 2021 | substance-related disorder | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT03482973 | Jun 2018 → Nov 2019 | coronary artery disorder | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03432650 | Jun 2018 → Dec 2020 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 3 | NCT03326180 | Mar 2018 → Feb 2021 | osteoarthritis, knee | University of Leeds | Completed | No outcome recorded |
| Phase 3 | NCT02933814 | Feb 2018 → Feb 2019 | — | Loma Linda University | Withdrawn | No outcome recorded |
| Phase 3 | NCT03351348 | Nov 2017 → Nov 2026 expected | breast cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 3 | NCT03303794 | Oct 2017 → Jun 2018 | — | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT03295721 | Oct 2017 → Jan 2018 | — | Heron Therapeutics | Completed | Met primary |
| Phase 3 | NCT03214510 | Oct 2017 → Jul 2027 expected | hepatobiliary disorder | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03261193 | Sep 2017 → Jun 2018 | neuropathy, painful | Nicholas Schott | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03262688 | Jun 2017 → Jan 2024 | — | Innocoll | Unknown | No outcome recorded |
| Phase 3 | NCT03151434 | Feb 2017 → Jul 2018 | — | Indiana University | Completed | No outcome recorded |
| Phase 3 | NCT01994967 | Nov → Dec 2016 | vertebral column disorder | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02949674 | Sep → Oct 2016 | — | Mexican Social Security Institute | Completed | No outcome recorded |
| Phase 3 | NCT02740114 | Aug 2016 → Jul 2020 | female reproductive organ cancer | M.D. Anderson Cancer Center | Terminated | Missed primary |
| Phase 3 | NCT03304444 | Aug 2016 → Oct 2017 | female reproductive organ cancer | Abington Memorial Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02336529 | Jul 2016 → Jul 2017 | breast cancer, neuropathy, painful | Kenneth Geving Andersen | Unknown | No outcome recorded |
| Phase 3 | NCT05004506 | Apr 2016 → Dec 2022 | chronic pain syndrome | Loyola University | Unknown | No outcome recorded |
| Phase 3 | NCT02601027 | Nov 2015 → Sep 2019 | female breast carcinoma | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT02525133 | Sep 2015 → Apr 2016 | — | Innocoll | Completed | Met primary |
| Phase 3 | NCT02517905 | Aug 2015 → Jan 2016 | dental pulp disorder | Pacira Pharmaceuticals, Inc | Completed | Missed primary |
| Phase 3 | NCT02523599 | Aug 2015 → Apr 2016 | neuropathy, painful | Innocoll | Completed | Met primary |
| Phase 3 | NCT02752971 | Feb 2015 → Feb 2016 | — | Hospital Central Dr. Luis Ortega | Completed | No outcome recorded |
| Phase 3 | NCT03720223 | Jan 2015 → Oct 2017 | urethral stricture | Urology of Virginia | Completed | No outcome recorded |
| Phase 3 | NCT02480621 | Dec 2014 → Jun 2016 | — | Jamaica Hospital Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02299167 | Jan → Sep 2014 | — | Imam Abdulrahman Bin Faisal University | Completed | No outcome recorded |
| Phase 3 | NCT02282774 | Dec 2013 → Jun 2014 | — | King Saud University | Completed | No outcome recorded |
| Phase 3 | NCT02065219 | Nov 2013 → Apr 2014 | chronic pain syndrome | University of Copenhagen | Completed | No outcome recorded |
| Phase 3 | NCT02065804 | Oct 2013 → Jul 2014 | chronic pain syndrome | University of Copenhagen | Completed | No outcome recorded |
| Phase 3 | NCT01986049 | Feb → Aug 2013 | — | New York Presbyterian Brooklyn Methodist Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02662660 | Jan 2012 → Dec 2015 | — | Hospital General Universitario Elche | Completed | No outcome recorded |
| Phase 3 | NCT01318590 | Nov 2011 → Jun 2019 | chronic pancreatitis | University of Montreal Hospital Centre (CHUM) | Terminated | No outcome recorded |
| Phase 3 | NCT01367418 | Sep 2010 → Mar 2012 | prostate cancer | Örebro University, Sweden | Completed | No outcome recorded |
| Phase 3 | NCT01314144 | Aug 2010 → Jul 2011 | breast cancer | Cork University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01079455 | May 2010 → Jul 2012 | osteoarthritis, hip | University Hospital Pellenberg | Unknown | No outcome recorded |
| Phase 3 | NCT01052012 | Dec 2009 → Sep 2011 | — | Durect | Completed | Missed primary |
| Phase 3 | NCT03713762 | Oct → Nov 2009 | — | Centro Medico Docente la Trinidad | Completed | No outcome recorded |
| Phase 3 | NCT00890682 | Apr → Nov 2009 | toe, misshapen | Pacira Pharmaceuticals, Inc | Completed | Met primary |
| Phase 3 | NCT00405262 | May 2006 → Oct 2008 | — | The Hospital for Sick Children | Completed | Missed primary |
| Phase 3 | NCT00332735 | May 2006 → Jan 2007 | — | Reinier de Graaf Groep | Completed | No outcome recorded |
| Phase 3 | NCT00358280 | Apr → Sep 2006 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00287326 | Jan → Jun 2006 | — | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 3 | NCT00197353 | Mar → Sep 1999 | — | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 3 | NCT00197327 | Feb 1998 → Mar 2000 | — | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 3 | NCT01308047 | — | — | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01303107 | — | — | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 4307 trials · 10 met primary · 25 missed | ||||||
| Phase 4 | NCT07216586 | Jan 2027 → Jan 2028 expected | osteoarthritis, knee | University of Miami | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07246642 | Nov 2026 → Nov 2027 expected | erectile dysfunction | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07684365 | Oct 2026 → Dec 2027 expected | — | Beth Israel Deaconess Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07855341 | Oct 2026 → Aug 2027 expected | — | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07606911 | Oct 2026 → Jul 2027 expected | — | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07813988 | Oct 2026 → Nov 2027 expected | lumbar disk disease, radiculopathy | Benha University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07570940 | Sep 2026 → Sep 2030 expected | atrial fibrillation, coronary artery disorder | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07795203 | Aug 2026 → Sep 2027 expected | — | Tongliao City People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07650760 | Jul → Dec 2026 expected | — | Wah Medical college , POF hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07684989 | Jul 2026 → Jun 2027 expected | — | Mayo Hospital Lahore | Not yet recruiting | No outcome recorded |
| Show all 307 trials opens the full record — a long page | ||||||
| Phase not applicable253 trials · 8 met primary · 10 missed | ||||||
| — | NCT07818512 | Sep 2026 → Nov 2027 expected | chronic pain syndrome | Bakirkoy Dr. Dr. Sadi Konuk Research and Training Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07854158 | Sep 2026 → Aug 2027 expected | — | Sargodha Medical College | Not yet recruiting | No outcome recorded |
| — | NCT07661212 | Sep 2026 → Sep 2027 expected | — | Bakirkoy Dr. Dr. Sadi Konuk Research and Training Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07794852 | Aug → Nov 2026 expected | — | Istanbul University | Enrolling by invitation | No outcome recorded |
| — | NCT07784192 | Aug → Oct 2026 | — | Selcuk University | Completed | No outcome recorded |
| — | NCT07824466 | Aug 2026 → Jul 2027 expected | — | Menoufia University | Recruiting | No outcome recorded |
| — | NCT07721571 | Jul 2026 → Jan 2027 expected | nephrolithiasis | Hitit University | Recruiting | No outcome recorded |
| — | NCT07658521 | Jul → Dec 2026 expected | — | Ain Shams University | Enrolling by invitation | No outcome recorded |
| — | NCT07651722 | Jun → Sep 2026 overdue | paralytic ileus | Tianjin First Central Hospital | Recruiting | No outcome recorded |
| — | NCT07853339 | Jun → Sep 2026 | — | Benha University | Completed | No outcome recorded |
| Show all 253 trials opens the full record — a long page | ||||||
| Phase not stated1 trial | ||||||
| — | NCT03969875 | Aug 2018 → Apr 2022 | osteoarthritis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Comparator or background therapy1,368 trials | ||||||
| Phase 0 | NCT07866508 Comparator | Aug → Oct 2026 expected | — | Sheikh Khalifa Bin Zayed Al Nahyan Combined Military Hospital Muzaffarabad | Active not recruiting | No outcome recorded |
| Phase 0 | NCT07485127 Comparator | Feb → Aug 2026 overdue | — | Sohag University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT07108465 Comparator | Jul → Sep 2025 overdue | impacted teeth, multiple | Henrique Tedesco | Recruiting | No outcome recorded |
| Phase 0 | NCT06617949 Comparator | Jan 2025 → Dec 2027 expected | substance-related disorder | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 0 | NCT06680167 Comparator | Oct 2024 → Nov 2025 | — | Sohag University | Completed | No outcome recorded |
| Show all 1,368 trials opens the full record — a long page | ||||||
Press releases naming this drug 106 releases
Evidence & citations 80 cited values
Every value below carries the sentence it was read from. 2,198 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bupivacaine | “patients whose labor analgesia is maintained using PIEB with low-volume bolus (6.25 mL) of a higher local anesthetic concentration solution (0.1% bupivacaine with fentanyl 2.0...” NCT03553576 ↗1942“The procedure will be completed by applying the first injection to the femoral triangle (10 ml of local anesthetic solution), the second injection to the subsartorial region...” NCT05566561 ↗ “Suprascapular nerve block with Bipuvacaine: a 50mm 22G needle (Stimuplex, BBraun) was introduced up to the suprascapular fossa, guided by ultrasound, and the location was...” NCT05778422 ↗ “Patients in Group A will receive unilateral spinal anaesthesia. The anesthesiologist will inject a small dose of 0.5% hyperbaric bupivacaine through a pencil-point spinal...” NCT07854158 ↗ “After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with...” NCT02622893 ↗ “For patient undergoing total knee replacement arthroplasty, patients injected intrathecally with bupivacaine 8 mg were compared with those with bupivacaine 8 mg with 25 mcg of...” NCT01261078 ↗ “A formulation of bupivacaine, given as a single injection after surgery, that could provide adequate, continuous, and extended pain relief would greatly simplify postoperative...” NCT00485667 ↗ “The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two...” NCT06349772 ↗ “Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric...” NCT05897151 ↗ “USG with a 25G needle, Bupivacaine 0.5% 30ml with 4mg preservative free dexamethasone divided as follows into the following 5 nerves: Posterior Tibial nerve (10ml), Saphenous...” NCT05368012 ↗ “Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable...” NCT03769714 ↗ |
| Known as | 0.25% Bupivacaine | “0.25% Bupivacaine” NCT02822196 ↗ |
| Known as | 0.5% bupivacaine, marcaine. | “0.5% bupivacaine, marcaine.” NCT01759524 ↗ |
| Known as | ANAWIN heavy | “0.5% hyperbaric bupivacaine (ANAWIN heavy, Neon Laborotaries, India) 10mg (2ml)” NCT06367660 ↗ |
| Known as | BPV | “bupivacaine (BPV)” PMID 34730810 ↗ Jan 2022 |
| Known as | Bucain | “with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl” NCT05806307 ↗ |
| Known as | Bucaine | “12 mg of isobaric "Bupivacaine 0.5%", "Bucaine®," (2.4 ml)” NCT06769737 ↗ |
| Known as | BUP | “We report the results of injection of bupivacaine (BUP) and botulinum toxin (BT) into agonist and antagonist muscles, respectively, to treat horizontal strabismus.” PMID 20126486 ↗ Dec 2009 |
| Known as | bupivacain | “The aim of this study is to assess the efficacy of Mg sulfate ( 10% ) as an adjuvant to Bupivacain ( 0.25 % ) in an U.S guided QLB for postoperative analgesia and postoperative...” NCT06301789 ↗57“Postoperatively the epidural anesthesia is continued until the morning of the third postoperative day using bupivacain 1 mg/ml, fentanyl 2 µg/ml and epinephrine 2µg/ml.” NCT02026687 ↗ “epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml” NCT02030717 ↗ “Ultrasound guided bilateral parasternal injection of bupivacain 0.375%, 20ml, at 4th thoracic vertebral level.” NCT05681507 ↗ “20 mg Kenacort + 1 ml Bupivacain (2.5 mg/ml) will be injected into the affected facet joints.” NCT05852808 ↗ “0.5% bupivacaine (Bupivacain®) will be administered.” NCT01945554 ↗ “Bupivacain 25% (Erector Spinae Plane Block)” NCT06422182 ↗ “Bupivacain will be injected at port sites.” NCT02969187 ↗ “Drug: Bupivacain (preoperative)” NCT06721832 ↗ “Bupivacain (B) group” NCT06076707 ↗ “Drug: Bupivacain” NCT05474001 ↗ |
| Known as | Bupivacain 1,25 mg/ml | “Bupivicaine 1.25mg/ml (BUPIVACAIN Sintetica 0.125 % ™ (Bupivacain 1,25 mg/ml), Sintetica-Bioren, Couvet, Schweiz)” NCT02414373 ↗ |
| Known as | BUPIVACAIN Sintetica | “Bupivicaine 1.25mg/ml (BUPIVACAIN Sintetica 0.125 % ™ (Bupivacain 1,25 mg/ml), Sintetica-Bioren, Couvet, Schweiz)” NCT02414373 ↗ |
| Known as | Bupivacaina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01596660 ↗ |
| Known as | Bupivacaine 0.25% epidural solution | “Bupivacaine 0.25% epidural solution” NCT03715517 ↗ |
| Known as | Bupivacaine = Marcain | “Bupivacaine = Marcain” NCT01367418 ↗ |
| Known as | Bupivacaine Collagen Sponge | “Drug: Bupivacaine Collagen Sponge” NCT01220024 ↗ |
| Known as | Bupivacaine Extended Release Liposome Injection | “Bupivacaine Extended Release Liposome Injection (Exparel TM) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the...” NCT03318757 ↗1“Bupivacaine extended-release liposome injection is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia.” PMID 22067185 ↗ Dec 2011 |
| Known as | Bupivacaine HCI | “Bupivacaine HCI (1.8mL) 5% concentration, with epinephrine (1:200,000) is the investigational product.” NCT04787731 ↗ |
| Known as | Bupivacaine HCl | “Bupivacaine HCl (Marcaine) is a local anesthetic that reduces the flow of sodium in and out of nerves which decreases the initiation and transfer of nerve signals in the area...” NCT03318757 ↗55“Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment...” NCT02624856 ↗ “A novel bupivacaine implant, XARACOLL (bupivacaine HCl), is Food and Drug Administration approved for treatment of acute postsurgical pain following adult inguinal herniorrhaphy.” PMID 37076252 ↗ Apr 2023 “Immediately prior to surgical wound closure, participants randomized to the bupivacaine arm will be injected with bupivacaine HCl along the closure site.” NCT04260854 ↗ “The random number generator feature in REDcap will be used to randomly assign subjects to receive the standard Bupivacaine HCl ACB or the Exparel ACB.” NCT04764916 ↗ “Evaluate the efficacy of intercostal nerve block using SKY0402 compared to epidural bupivacaine HCl in subjects undergoing posterolateral thoracotomy.” NCT00807209 ↗ “The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg.” NCT03743194 ↗ “Bilateral abdominal Lap-TAP block injection near incision site with 0.25% Bupivacaine HCl (30cc) with 30ml being injected bilaterally.” NCT04655339 ↗ “with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl” NCT05806307 ↗ “bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline” NCT00492973 ↗ “Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)” NCT06702202 ↗ |
| Known as | Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000) | “Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)” NCT00485693 ↗ |
| Known as | Bupivacaine Hcl 0.25% Inj | “Drug: Bupivacaine Hcl 0.25% Inj” NCT03541941 ↗ |
| Known as | Bupivacaine heavy | “Spinal anesthesia with Bupivacaine heavy 40 mg and Morphine 250 micro grams will be given to patient in addition to the routine general anesthesia before the start of surgery” NCT03013075 ↗ |
| Known as | bupivacaine hydrochloride | “Bupivacaine Hydrochloride is 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-monohydrochloride, monohydrate, a white crystalline powder that is freely soluble in 95...” NCT03672500 ↗112“This is a prospective, single-institution, parallel-group, single-blinded, randomized-controlled, two-arm, effectiveness study comparing bupivacaine liposomal injectable...” NCT02111746 ↗ “Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with...” NCT03242668 ↗ “Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and...” NCT03176459 ↗ “Patients will receive a pre-closure local infiltration of 266 mg liposomal bupivacaine (20 mL for single-level surgery; 30 mL for two-level surgery) combined with 25 mg...” NCT07171125 ↗ “A total of 9 ml of Bupivacaine-Hydrochloride (Marcaine) 0.5%, or Sodium-Chloride 0.9%, as a placebo, were injected subcutaneously to the trocar sites (3 ml to each trocar...” PMID 33420214 ↗ Jan 2021 “Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block” NCT03541941 ↗ “We implanted four XaraColl implants each containing 50 mg of bupivacaine hydrochloride (200 mg total dose) in ten men undergoing laparoscopic inguinal or umbilical hernioplasty.” PMID 23390367 ↗ Feb 2013 “10 mL of 0.25% Bupivacaine Hydrochloride (HCL) will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.” NCT04353414 ↗ “After mesh placement, a long-acting local anesthetic (bupivacaine hydrochloride, 0.50%) or placebo (0.9% normal saline) was injected between the mesh and the peritoneum.” PMID 26154700 ↗ Sep 2015 “Lidocaine and bupivacaine hydrochloride (HCl) are the most commonly used drugs for wound infiltration during laparoscopic surgery for post-operative pain control.” NCT02352922 ↗ |
| Known as | Bupivacaine Hydrochloride (HCl) | “A Multicenter, Randomized, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Analgesic Effect of the INL-001 Bupivacaine Hydrochloride (HCl)...” NCT03262688 ↗ |
| Known as | Bupivacaine hydrochloride 0.5% ( Marcaine Spinal, 5 mg/ml, AstraZeneca, Missisipi, ON, Canada) | “Bupivacaine hydrochloride 0.5% ( Marcaine Spinal, 5 mg/ml, AstraZeneca, Missisipi, ON, Canada)” NCT01558713 ↗ |
| Known as | Bupivacaine Hydrochloride Injection USP | “Administration of Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®) as single-dose into the cutaneous,...” NCT05193227 ↗ |
| Known as | Bupivacaine hydrogen chloride | “Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine” NCT03094481 ↗ |
| Known as | Bupivacaine hydrogen chloride (HCl) | “Bupivacaine hydrogen chloride (HCl) 0.025 % in 15+15 ML Injection” NCT04947007 ↗ |
| Known as | Bupivacaine liposomal | “Drug: Bupivacaine liposomal” NCT02890199 ↗ |
| Known as | Bupivacaine Liposomal Injectable Suspension | “The effectiveness of an Exparel Block (Bupivacaine Liposomal Injectable Suspension) for post-operative pain control has been well studied with encouraging results.” NCT04910165 ↗ |
| Known as | bupivacaine liposomal injectable suspension (Exparel) | “bupivacaine liposomal injectable suspension (Exparel®)” NCT02111746 ↗ |
| Known as | Bupivacaine liposome | “Dilute 266mg of bupivacaine liposome with saline solution to 30ml.” NCT06135545 ↗ |
| Known as | bupivacaine liposome extended-release injectable suspension | “This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is...” NCT01507220 ↗ |
| Known as | Bupivacaine Liposome Injectable Suspension | “Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable...” NCT03769714 ↗6“Solution of: 266mg of Bupivacaine Liposome Injectable Suspension (Exparel) mixed with 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%)...” NCT03541941 ↗ “A new sustained-release local anesthetic solution (Bupivacaine Liposome Injectable Suspension) will be injected into the soft tissues around the join after surgery.” NCT02682498 ↗ “10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline” NCT02713230 ↗ “EXPAREL (bupivacaine liposome injectable suspension)” NCT01507246 ↗ “EXPAREL (bupivacaine liposome injectable suspension)” NCT04518462 ↗ |
| Known as | Bupivacaine Liposome Injection | “Drug: Bupivacaine Liposome Injection” NCT02341079 ↗ |
| Known as | bupivacaine liposome suspension 1.3% | “0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\], i.m.)” NCT03420638 ↗ |
| Known as | Bupivacaine Patch | “Bupivacaine TTS (Bupivacaine Patch)” NCT01096966 ↗ |
| Known as | Bupivacaine TTS | “Bupivacaine TTS (Bupivacaine Patch)” NCT01096966 ↗1“Bupivacaine TTS [Eladur™]” NCT00478179 ↗ |
| Known as | bupivacaine: Marcaine | “Bupivacaine: Marcaine®” NCT02086474 ↗ |
| Known as | bupivacine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04668456 ↗ |
| Known as | Bupivicaine | “This study aims to compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine versus bupivacaine with morphine” NCT02566096 ↗4“standard bupivicaine (combination of ropivacaine 0.5% and lidocaine 2%)” NCT04180943 ↗ “Stellate Ganglion Block Injection with Bupivicaine” NCT02907983 ↗ “Local anesthetic (Bupivicaine)” NCT03004222 ↗ “Drug: Bupivicaine” NCT01986049 ↗ |
| Known as | Bupivicaine HCl | “Drug: Bupivicaine HCl” NCT03015532 ↗ |
| Known as | Bustesin | “Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour” NCT02824770 ↗ |
| Known as | Buvanest Spinal 0.5% Heavy | “10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy)” NCT02716129 ↗ |
| Known as | Buvasin | “a dose of 0.25% bupivacaine (Buvasin %5 flakon) 20ml will be injected here.” NCT06084403 ↗ |
| Known as | Buvicaine HCl %0.5 | “20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture” NCT04756050 ↗ |
| Known as | Carbostesin | “10 ml of 5% bupivacaine (Carbostesin®) was used for each side.” NCT00472446 ↗ |
| Known as | CollaRx Bupivacaine implant | “The CollaRx Bupivacaine implant is a thin flat sponge made out of collagen that comes for cow tendons and contains bupivacaine.” NCT00661466 ↗ |
| Known as | DepoFoam bupivacaine | “The authors evaluate the extent and duration of analgesia achieved with extended-release DepoFoam bupivacaine (Pacira Pharmaceuticals, Inc., Parsippany, New Jersey) in patients...” PMID 22179931 ↗ Dec 20111“DepoFoam® bupivacaine (Pacira Pharmaceuticals, Inc., San Diego, CA, USA), an extended-release liposomal bupivacaine-based analgesic, was compared with placebo for the...” PMID 21842428 ↗ Aug 2011 |
| Known as | Eladur | “Bupivacaine TTS [Eladur™]” NCT00478179 ↗ |
| Known as | EXPAREL | “Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with...” NCT03731221 ↗156“The purpose of the study is to determine the plasma concentration of bupivacaine at various time points after Exparel (bupivacaine liposome injectable suspension, Pacira...” NCT04685421 ↗ “Patients then received either a 40-mL suspension of 20 mL Exparel (1 vial of bupivacaine liposome injectable suspension) and 20 mL 0.9% injectable saline or 20 mL 0.5%...” PMID 27159290 ↗ Apr 2016 “At the end of the Septorhinoplasty while the patient is still under general anesthesia, an associate investigator assisting in the case will administer liposomal bupivacaine...” NCT06989866 ↗ “The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two...” NCT06349772 ↗ “This will be a comparative study between two cohorts of patients undergoing Roux-en-Y Gastric bypass. One cohort (75 patients) will receive FDA approved Exparel® (liposome...” NCT03187379 ↗ “Local infiltration of liposomal bupivacaine (EXPAREL Pacira Pharmaceuticals, Inc., Parsippany, New Jersey) may provide longer-lasting pain relief when compared to single shot...” NCT03474510 ↗ “This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is...” NCT01507220 ↗ “Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable...” NCT03769714 ↗ “This is a prospective, single-institution, parallel-group, single-blinded, randomized-controlled, two-arm, effectiveness study comparing bupivacaine liposomal injectable...” NCT02111746 ↗ “The purpose of this study is to assess pharmacokinetics of liposomal bupivacaine (Exparel) after multilevel intercostal injections of this local anesthetic for pain control...” NCT03737292 ↗ |
| Known as | Exparel, liposomal bupivacaine | “Exparel, liposomal bupivacaine” NCT03730402 ↗ |
| Known as | ExparelTM | “ExparelTM is an FDA-approved liposomal formulation of bupivacaine that allows for 72 hours of postsurgical analgesia with a single injection.” NCT02214810 ↗ |
| Known as | Heavy Bupivacaine | “In this group ,participants are given 1.6 ml of Injection Heavy Bupivacaine 0.5% initially followed by 0.9ml after 60 seconds at a rate of 0.2ml/hr.” NCT06620614 ↗ |
| Known as | hydrochloride bupivacaine | “20 ml of 0.75% hydrochloride bupivacaine is diluted with 10 ml saline and divided into three 10 ml doses.” NCT07049094 ↗ |
| Known as | Hyperbaric Bupivacaine | “Comparative Study on Fractionated Versus Bolus Dose of Hyperbaric Bupivacaine in Patients Undergoing Transurethral Resection of Prostate Surgery Under Subarachnoid Block.” NCT06620614 ↗1“Drug: Hyperbaric bupivacaine” NCT05017584 ↗ |
| Known as | INL-001 | “A Multicenter, Randomized, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Analgesic Effect of the INL-001 Bupivacaine Hydrochloride (HCl)...” NCT03262688 ↗4“The MATRIX-1 and MATRIX-2 studies examined the efficacy and safety of the bioresorbable bupivacaine HCl collagen-matrix implant (INL-001) for postsurgical pain after open...” PMID 30467808 ↗ Nov 2018 “A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients...” NCT04785625 ↗ “INL-001 is a bupivacaine HCl collagen-matrix implant that provides extended delivery of bupivacaine directly at the site and avoids the risk of accidental injection.” PMID 33237534 ↗ Nov 2020 “INL-001 (bupivacaine hydrochloride) implant” NCT04785638 ↗ |
| Known as | Liposomal bupivacaine | “Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with...” NCT03731221 ↗122“This study seeks to determine whether a new sustained-release local anesthetic solution (Exparel - Liposomal Bupivacaine) injected into the soft tissues around the joint after...” NCT02682498 ↗ “This double-blind, multicenter trial evaluated the efficacy, safety, and pharmacokinetics of single-injection, ultrasound-guided brachial plexus block (BPB) with liposomal...” PMID 31150095 ↗ Feb 2020 “The purpose of this research is to find out if using liposomal bupivacaine solution (bupivacaine liposome) injections during lower extremity revascularization surgery will...” NCT05992896 ↗ “To investigate the efficacy, safety, pharmacodynamics, and pharmacokinetics of liposomal bupivacaine (LB) administered via ultrasound-guided sciatic nerve block in the...” PMID 38340677 ↗ Feb 2024 “Patients will receive a pre-closure local infiltration of 266 mg liposomal bupivacaine (20 mL for single-level surgery; 30 mL for two-level surgery) combined with 25 mg...” NCT07171125 ↗ “The purpose of this study is to learn how well Liposomal Bupivacaine (Exparel™) controls post-operative pain in patients undergoing both open and laparoscopic (minimally...” NCT02128646 ↗ “Compared to Standard Bupivacaine (SB), Liposomal Bupivacaine (LB) is a formulation designed to prolong the duration of action to up to 72 hours by slow release of bupivacaine...” NCT04928664 ↗ “Liposomal bupivacaine (Exparel, Pacira Pharmaceuticals Inc, Parsippany, New Jersey, USA) is a multivesicular formulation of bupivacaine that prolongs drug release and can...” NCT06740214 ↗ “20cc liposomal bupivacaine (1 vial; 266 mg) added to 30 cc normal saline to a total of 50 cc solution was injected into the periarticular tissues at the conclusion of the...” NCT06557018 ↗ “Liposomal bupivacaine, a long-acting form of bupivacaine, has been found to be effective for postoperative pain control after total knee, total hip and total shoulder arthroplasty.” NCT03149887 ↗ |
| Known as | Liposomal bupivacaine (LB) | “Drug: Liposomal bupivacaine (LB)” NCT07651722 ↗ |
| Known as | Liposomal Bupivicaine | “Exparel (Liposomal Bupivicaine)” NCT03975283 ↗1“Drug: Liposomal Bupivicaine” NCT07196631 ↗ |
| Known as | Liposome bupivacaine | “A novel formulation of bupivacaine, ie, liposome bupivacaine (Pacira Pharmaceuticals, Inc., Parsippany, NJ), has been developed to address the need for longer-acting local...” NCT03769714 ↗7“The purpose of this study was to investigate if the addition of liposome bupivacaine (LB) to an interscalene block (ISB) had an effect on the number of patients with surgical-...” PMID 32280340 ↗ Mar 2020 “We examined whether liposome bupivacaine (Exparel) given in the interscalene brachial plexus block lowers pain in the setting of multimodal postoperative pain management for...” PMID 28157791 ↗ May 2017 “OBJECTIVE: Assess comparative efficacy of liposome bupivacaine administered at doses ≤266 mg and bupivacaine HCl administered at doses ≤200 mg for postsurgical analgesia.” PMID 22900785 ↗ Sep 2012 “Liposome bupivacaine is a new long-acting local anesthetic approved by the FDA, offering pain relief for up to 72 hours compared to regular bupivacaine's 8-hour duration.” NCT07049094 ↗ “The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for intercostal nerve block in subjects undergoing posterolateral thoracotomy.” NCT01802411 ↗ “Liposome bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE Study pooled analysis.” PMID 25018650 ↗ Jun 2014 “Liposome bupivacaine (Exparel) has been approved as a single dose infiltration for longer postoperative period analgesic.” NCT02969187 ↗ |
| Known as | Marcain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04854395 ↗ |
| Known as | Marcain spinal | “The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine...” NCT02026687 ↗ |
| Known as | Marcaine | “The use of Marcaine (bupivacaine) is indicated for local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic...” NCT05638620 ↗77“Administration of Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®) as single-dose into the cutaneous,...” NCT05193227 ↗ “Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline” NCT03176758 ↗ “The cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.” NCT05738759 ↗ “Multimodal local injection of bupivacaine (Marcaine), morphine sulfate (Duramorph), ketorolac (Toradol) given at the fracture site at the time of hip fracture surgery” PMID 37199438 ↗ Sep 2023 “Bupivacaine HCl (Marcaine) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.” NCT06077422 ↗ “All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.” NCT05144828 ↗ “Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.” NCT02723487 ↗ “Treatment group receives Marcaine (Bupivacaine) injected into one breast following breast reduction surgery and a saline injection in the other group.” NCT04494880 ↗ “The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)” NCT04212949 ↗ “Marcaine hydrochloride (bupivacaine) without epinephrine 0.5% was chosen for this study because this was used in previous studies” NCT06842771 ↗ |
| Known as | Marcaine (bupivacaine) | “Marcaine (bupivacaine)” NCT05019638 ↗ |
| Known as | Marcaine hydrochloride | “Marcaine hydrochloride (bupivacaine) without epinephrine 0.5% was chosen for this study because this was used in previous studies” NCT06842771 ↗ |
| Known as | Marcaine Spinal Heavy | “A predetermined small dose of hyperbaric bupivacaine (Marcaine Spinal Heavy; Astra Zeneca, Lund, Sweden) which was prepared in1 mL tuberculin syringe was injected.” NCT02299167 ↗ |
| Known as | MarcaineTM | “with hyperbaric bupivacaine 0.5% (MarcaineTM, Hospira) and fentanyl” PMID 30881909 ↗ Feb 2019 |
| Known as | ND-340 | “The current investigational product, ND-340, is a bupivacaine microsphere injection with an extended release profiling.” NCT05588557 ↗ |
| Known as | Novabupi | “Hyperbaric Novabupi® (Bupivacaine S75: R25) Compared to Hyperbaric Neocaine® (Bupivacaine S50: R50) in Spinal Anesthesia in Lower Limbs Vascular Surgery” NCT03883763 ↗ |
| Known as | plain bupivacaine | “Nerve block with (B-LB): A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared” NCT05736549 ↗ |
| Known as | POSIMIR bupivacaine solution | “POSIMIR® bupivacaine solution” NCT01052012 ↗ |
| Known as | pubivicaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05350696 ↗ |
| Known as | SABER-Bupivacaine | “SABER-Bupivacaine is an investigational extended-release formulation of bupivacaine in a resorbable matrix, which may provide up to 72 h of local pain relief.” PMID 22510183 ↗ Jun 20111“This is a research study testing SABER-Bupivacaine (an experimental pain-relieving medication).” NCT01052012 ↗ |
| Known as | sensorcaine | “Patients assigned to bupivacaine will receive a single spinal injection of 7.5 mg of bupivacaine. (other name: pure Sensorcaine 0.75% diluted with normal saline to a total...” NCT03305575 ↗3“Bupivacaine Hydrochloride (Brand Name: Marcaine, Sensorcaine) Dosage Form: Injection Dosage: 3 ml vial, 0.5% solution” NCT02571283 ↗ “bupivacaine (known as marcaine or sensorcaine commercially)” NCT06450028 ↗ |
| Known as | sunnypivacaine | “patients will receive 18 ml 0.5% bupivacaine (Sunnypivacaine®) using Ultrasound-Guided TAP Block Technique” NCT06720337 ↗1“bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml” NCT06133881 ↗ |
| Known as | XaraColl | “Clinical evaluation of XaraColl(®), a bupivacaine-collagen implant, for postoperative analgesia in two multicenter, randomized, double-blind, placebo-controlled pilot studies.” PMID 22792007 ↗ Jun 2012 |
| Known as | XARACOLL (bupivacaine hydrochloride) Implant | “XARACOLL (bupivacaine hydrochloride) Implant” NCT04785638 ↗1“XARACOLL (bupivacaine hydrochloride) Implant” NCT04785625 ↗ |
| Action | Inhibit | “selective inhibition by local anesthetics of cellular Gq proteins explains this effect” NCT00600158 ↗ |
| Modality | Other / unclassified | “the two local anaesthetics” NCT00801138 ↗ |
| Route | Other | “All patients will receive local anesthesia injections preoperatively (either 2% lidocaine or 0.5% bupivacaine)” NCT00050362 ↗ |